{"id":41442,"date":"2025-12-11T22:57:00","date_gmt":"2025-12-11T15:57:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=41442"},"modified":"2025-12-11T22:57:00","modified_gmt":"2025-12-11T15:57:00","slug":"everest-medicines-announces-commercialization-service-agreement-and-license-agreement-with-hasten","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=41442","title":{"rendered":"Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten"},"content":{"rendered":"

– Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease \u00a0leveraging Everest’s existing commercial organization
<\/i>– Exclusive Greater China<\/span> license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the Company’s late-stage product pipeline
<\/i>– Together, these agreements drive financial and strategic synergies, <\/i>\u00a0improve utilization and productivity of our existing commercial platform, and strengthen commercial capabilities and life-cycle management, while establishing an attractive vertical in cardiovascular disease<\/i><\/p>\n

SHANGHAI<\/span><\/span>, Dec. 11, 2025<\/span><\/span> \/PRNewswire\/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that its wholly-owned subsidiary, Everest Medicines (China<\/span>) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest’s existing sales and marketing organization to provide commercialization services for a portfolio of Hasten’s mature assets.<\/p>\n

The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is expected to be indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China<\/span>. The Commercial Services Agreement is expected to close in 1H 2026, subject to customary closing conditions, while the Licensing Agreement will close immediately. Both agreements do not impact Everest’s 2025 financial guidance.<\/p>\n

Everest is expected to benefit from these two transactions by realizing synergies from XERAVA and Hasten’s critical care portfolio including Rocephin and Stilamin across complementary geographic footprints, channel access and hospital coverage, and enhancing commercialization capabilities and life-cycle management of innovative medicines. Everest also expects to generate a recurring income stream from the service fees, thereby improving utilization and productivity of its existing commercial platform. By leveraging established infrastructure, sales team and key account relationships, the Company believes that it will be able to deliver incremental\u00a0 sales while enhancing the scale, experience and effectiveness of its own commercial organization. Together, these two agreements strengthen Everest’s commercial foundation in China<\/span> and expand its presence in the large and growing cardiovascular market. The potential approval of Lerodalcibep in Greater China<\/span> in 2027 is expected to contribute to future revenue growth within Everest’s cardiovascular portfolio.<\/p>\n

Commercialization Service Agreement Deal Terms:<\/b><\/p>\n

The Commercialization Service Agreement with Hasten covers six approved and commercially available products across three major therapeutic areas:<\/p>\n